Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 12 clinical trials
Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL

Background Hairy cell leukemia (HCL) does not usually respond to chemotherapy. Most people with HCL have a BRAF gene mutation. This can increase the growth of cancer cells. Vemurafenib has been tested to treat these people. However, researchers think a combination of drugs might work better. Objective To test if …

  • 0 views
  • 12 Sep, 2021
  • 1 location
Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib

+ ipilimumab alone in patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.

ct scan
BRAF
ipilimumab
measurable disease
metastatic melanoma
  • 11 views
  • 01 May, 2021
  • 52 locations
Dabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 Mutation

This is a single arm phase II trial focused on how dabrafenib and trametinib before and after surgery works in treating patients with stage IIIB-C melanoma that has a specific mutation in the BRAF gene. Dabrafenib and trametinib may stop the growth of tumor cells by blocking some of the …

neutrophil count
follicle stimulating hormone
braf v600 mutation
dabrafenib
thromboplastin
  • 10 views
  • 12 Apr, 2021
  • 1 location
Safety of ABM-1310 in Patients With Advanced Solid Tumors

with documented BRAF V600 mutation and locally advanced or metastatic solid tumors who have no effective standard treatment options available, as monotherapy in Part A, or in combination with

metastasis
neutrophil count
dexamethasone
cancer
solid tumour
  • 0 views
  • 23 Jun, 2021
  • 2 locations
Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma

The purpose of this study is to assess rate of disease relapse and hazard rate of disease relapse after neoadjuvant therapy based on the statuses of pathologic complete response or non-pathologic complete response, and postoperative adjuvant therapy.

  • 0 views
  • 20 Jul, 2021
  • 1 location
Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma

called BRAF V600 mutation. Radiation therapy uses high energy rays to kill tumor cells and reduce the size of tumors. Dabrafenib and trametinib may stop the growth of tumor cells by blocking BRAF and MEK

blood transfusion
gangliogliomas
dabrafenib
glomerular filtration rate
ganglioglioma
  • 129 views
  • 15 Sep, 2021
  • 56 locations
Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer

This phase II trial studies how well encorafenib and binimetinib given with or without nivolumab works in treating patients with BRAF V600 mutation positive thyroid cancer that has spread to

  • 0 views
  • 04 Feb, 2021
  • 1 location
Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)

Background GBM refers to a specific kind of brain cancer called glioblastoma. The standard treatment for GBM is radiation plus temozolomide, an oral chemotherapy drug. Pembrolizumab is an immune therapy that is now used to treat other cancers. The addition of pembrolizumab to the standard treatment of radiation and temozolomide …

carmustine implant
aptt
blood transfusion
neutrophil count
temozolomide
  • 240 views
  • 12 Sep, 2021
  • 20 locations
Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG

The goal of this study is to estimate the efficacy of encorafenib and binimetinib as measured by radiographic response in recurrent high-grade primary brain tumors.

BRAF
primary brain neoplasm
cancer
serum pregnancy test
hydroxychloroquine
  • 24 views
  • 15 Sep, 2021
  • 9 locations
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors Non-Hodgkin Lymphoma or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)

This phase II Pediatric MATCH trial studies how well vemurafenib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with BRAF V600 mutations that have spread to other places in the body (advanced) and have come back (recurrent) or do not respond to treatment (refractory). Vemurafenib may …

bone marrow procedure
cancer treatment
autologous stem cell infusion
metastatic disease
metastasis
  • 236 views
  • 22 Aug, 2021
  • 76 locations